Ten complete MD Final examination sets with a fixed four-paper architecture. Every paper contains ten 10-mark questions drawn from ten different specialties/domains, with hidden answers and strict paper-specific scope.
FREE SAMPLE: Set 1 is fully open with all four papers and complete hidden answers. Sets 2–10 are available to registered members. Login / Register for Full Access
10Exam sets
4Fixed papers per set
400Total questions
100Marks per paper
Permanent four-paper structure: Paper I — Applied Basic Sciences, Pathophysiology & Foundations Paper II — Comprehensive Clinical Medicine & Allied Specialties Paper III — Infectious & Tropical Medicine Paper IV — Recent Advances, Contemporary Therapeutics, Diagnostics & Precision Medicine
Diversity rule: within every paper of every set, all 10 questions come from 10 different specialties/domains—no same-specialty clustering.
SET 1 • PAPER 1
Paper 1: Applied Basic Sciences, Pathophysiology & Foundations
10 Questions × 10 marks = 100 marks • 10 different specialties/domains • Strict paper-specific scope • MD Final level
Q1 • Neurology • Neurophysiology • 10 marks
Integrate the topic with complications, monitoring and translational relevance of autonomic nervous system physiology in the context of Neurophysiology. Illustrate how the underlying mechanism explains the clinical and laboratory phenotype.
Autonomic Nervous System Physiology — MD Final answer
1. Core concept and mechanistic basis Sympathetic outflow is thoracolumbar and predominantly adrenergic at the effector organ; parasympathetic outflow is craniosacral and cholinergic. Baroreflex afferents travel through IX/X to the nucleus tractus solitarius; autonomic failure produces orthostatic hypotension, impaired heart-rate variability and characteristic pupillary/sudomotor abnormalities.
2. Pathophysiological sequence Present the sequence as trigger → molecular/cellular response → organ dysfunction → compensatory response → decompensation. Explicitly identify the rate-limiting or clinically decisive step and explain how it produces the phenotype rather than merely listing associations.
3. Clinicopathological correlation Relate the mechanism to the characteristic bedside findings and to the expected biochemical, haematological, ECG, imaging or physiological abnormalities. State which findings support the mechanism and which would suggest an alternative diagnosis.
4. Diagnostic interpretation Use pre-test probability and targeted testing. Interpret results in relation to timing, biological variation, organ function, drugs and important confounders; avoid treating a single abnormal laboratory value as diagnostic in isolation.
5. Translational and therapeutic relevance Show how understanding the pathway changes prevention, drug selection, monitoring or development of targeted therapy. Mention major safety constraints and why treatment may fail despite apparently correct pathway targeting.
6. High-yield conclusion A distinction-level answer should finish by linking mechanism, phenotype and therapeutic target in one coherent model and include a labelled flow diagram where appropriate.
Q2 • Clinical Pharmacology • Pharmacology foundations • 10 marks
Integrate the topic with complications, monitoring and translational relevance of therapeutic drug monitoring in the context of Pharmacology foundations. Illustrate how the underlying mechanism explains the clinical and laboratory phenotype.
Therapeutic Drug Monitoring — MD Final answer
1. Core concept and mechanistic basis TDM is most useful for drugs with a narrow therapeutic index, large pharmacokinetic variability and a measurable concentration–effect relationship. Interpret a correctly timed steady-state level with dose history, adherence, renal/hepatic function, albumin, interactions and the clinical response; examples include aminoglycosides, vancomycin, lithium, digoxin, valproate, carbamazepine and selected immunosuppressants.
2. Pathophysiological sequence Present the sequence as trigger → molecular/cellular response → organ dysfunction → compensatory response → decompensation. Explicitly identify the rate-limiting or clinically decisive step and explain how it produces the phenotype rather than merely listing associations.
3. Clinicopathological correlation Relate the mechanism to the characteristic bedside findings and to the expected biochemical, haematological, ECG, imaging or physiological abnormalities. State which findings support the mechanism and which would suggest an alternative diagnosis.
4. Diagnostic interpretation Use pre-test probability and targeted testing. Interpret results in relation to timing, biological variation, organ function, drugs and important confounders; avoid treating a single abnormal laboratory value as diagnostic in isolation.
5. Translational and therapeutic relevance Show how understanding the pathway changes prevention, drug selection, monitoring or development of targeted therapy. Mention major safety constraints and why treatment may fail despite apparently correct pathway targeting.
6. High-yield conclusion A distinction-level answer should finish by linking mechanism, phenotype and therapeutic target in one coherent model and include a labelled flow diagram where appropriate.
Q3 • Nephrology • AKI mechanisms • 10 marks
Integrate the topic with complications, monitoring and translational relevance of cardiorenal syndrome in the context of AKI mechanisms. Illustrate how the underlying mechanism explains the clinical and laboratory phenotype.
Cardiorenal Syndrome — MD Final answer
1. Core concept and mechanistic basis Cardiorenal syndromes reflect bidirectional heart–kidney injury. Reduced forward flow, renal venous congestion, RAAS/sympathetic activation, inflammation and raised intra-abdominal pressure can reduce GFR. Congestion rather than creatinine alone should guide decongestion; a modest creatinine rise during effective diuresis does not necessarily represent structural tubular injury.
2. Pathophysiological sequence Present the sequence as trigger → molecular/cellular response → organ dysfunction → compensatory response → decompensation. Explicitly identify the rate-limiting or clinically decisive step and explain how it produces the phenotype rather than merely listing associations.
3. Clinicopathological correlation Relate the mechanism to the characteristic bedside findings and to the expected biochemical, haematological, ECG, imaging or physiological abnormalities. State which findings support the mechanism and which would suggest an alternative diagnosis.
4. Diagnostic interpretation Use pre-test probability and targeted testing. Interpret results in relation to timing, biological variation, organ function, drugs and important confounders; avoid treating a single abnormal laboratory value as diagnostic in isolation.
5. Translational and therapeutic relevance Show how understanding the pathway changes prevention, drug selection, monitoring or development of targeted therapy. Mention major safety constraints and why treatment may fail despite apparently correct pathway targeting.
6. High-yield conclusion A distinction-level answer should finish by linking mechanism, phenotype and therapeutic target in one coherent model and include a labelled flow diagram where appropriate.
Q4 • Fluid & Electrolyte Medicine • Electrolyte physiology • 10 marks
Discuss the diagnostic/interpretive framework and key pitfalls of sodium-water balance and osmoregulation in the context of Electrolyte physiology. Illustrate how the underlying mechanism explains the clinical and laboratory phenotype.
Sodium-Water Balance And Osmoregulation — MD Final answer
1. Core concept and mechanistic basis Plasma tonicity is determined mainly by sodium salts and regulated by thirst and arginine vasopressin; extracellular volume is regulated mainly through renal sodium handling. Evaluate measured serum osmolality, glucose, urine osmolality and urine sodium. In chronic hyponatraemia avoid overly rapid correction because of osmotic demyelination; in hypernatraemia replace free water while treating the cause.
2. Pathophysiological sequence Present the sequence as trigger → molecular/cellular response → organ dysfunction → compensatory response → decompensation. Explicitly identify the rate-limiting or clinically decisive step and explain how it produces the phenotype rather than merely listing associations.
3. Clinicopathological correlation Relate the mechanism to the characteristic bedside findings and to the expected biochemical, haematological, ECG, imaging or physiological abnormalities. State which findings support the mechanism and which would suggest an alternative diagnosis.
4. Diagnostic interpretation Use pre-test probability and targeted testing. Interpret results in relation to timing, biological variation, organ function, drugs and important confounders; avoid treating a single abnormal laboratory value as diagnostic in isolation.
5. Translational and therapeutic relevance Show how understanding the pathway changes prevention, drug selection, monitoring or development of targeted therapy. Mention major safety constraints and why treatment may fail despite apparently correct pathway targeting.
6. High-yield conclusion A distinction-level answer should finish by linking mechanism, phenotype and therapeutic target in one coherent model and include a labelled flow diagram where appropriate.
Q5 • Airway & Allergy Medicine • Asthma pathobiology • 10 marks
Integrate the topic with complications, monitoring and translational relevance of beta-receptor pharmacology and bronchodilation in the context of Asthma pathobiology. Illustrate how the underlying mechanism explains the clinical and laboratory phenotype.
Beta-Receptor Pharmacology And Bronchodilation — MD Final answer
1. Core concept and mechanistic basis β2-receptors couple to Gs–adenylyl cyclase–cAMP, relaxing airway smooth muscle. Repeated agonist exposure can cause receptor phosphorylation/desensitisation; inhaled corticosteroids improve inflammatory control and β2 responsiveness. Tremor, tachycardia, hypokalaemia and lactate elevation are dose-related clues to excessive β-agonism.
2. Pathophysiological sequence Present the sequence as trigger → molecular/cellular response → organ dysfunction → compensatory response → decompensation. Explicitly identify the rate-limiting or clinically decisive step and explain how it produces the phenotype rather than merely listing associations.
3. Clinicopathological correlation Relate the mechanism to the characteristic bedside findings and to the expected biochemical, haematological, ECG, imaging or physiological abnormalities. State which findings support the mechanism and which would suggest an alternative diagnosis.
4. Diagnostic interpretation Use pre-test probability and targeted testing. Interpret results in relation to timing, biological variation, organ function, drugs and important confounders; avoid treating a single abnormal laboratory value as diagnostic in isolation.
5. Translational and therapeutic relevance Show how understanding the pathway changes prevention, drug selection, monitoring or development of targeted therapy. Mention major safety constraints and why treatment may fail despite apparently correct pathway targeting.
6. High-yield conclusion A distinction-level answer should finish by linking mechanism, phenotype and therapeutic target in one coherent model and include a labelled flow diagram where appropriate.
Q6 • Hematology • Hematopoiesis • 10 marks
Explain the mechanistic basis and its clinical consequences of erythropoietin and red-cell production in the context of Hematopoiesis. Illustrate how the underlying mechanism explains the clinical and laboratory phenotype.
Erythropoietin And Red-Cell Production — MD Final answer
1. Core concept and mechanistic basis Renal peritubular interstitial cells sense hypoxia through the HIF pathway and increase erythropoietin, which supports erythroid progenitor survival. CKD, inflammation/hepcidin excess, iron deficiency and marrow disease blunt erythropoiesis. Reticulocyte response, iron indices and the clinical context distinguish production failure from blood loss or haemolysis.
2. Pathophysiological sequence Present the sequence as trigger → molecular/cellular response → organ dysfunction → compensatory response → decompensation. Explicitly identify the rate-limiting or clinically decisive step and explain how it produces the phenotype rather than merely listing associations.
3. Clinicopathological correlation Relate the mechanism to the characteristic bedside findings and to the expected biochemical, haematological, ECG, imaging or physiological abnormalities. State which findings support the mechanism and which would suggest an alternative diagnosis.
4. Diagnostic interpretation Use pre-test probability and targeted testing. Interpret results in relation to timing, biological variation, organ function, drugs and important confounders; avoid treating a single abnormal laboratory value as diagnostic in isolation.
5. Translational and therapeutic relevance Show how understanding the pathway changes prevention, drug selection, monitoring or development of targeted therapy. Mention major safety constraints and why treatment may fail despite apparently correct pathway targeting.
6. High-yield conclusion A distinction-level answer should finish by linking mechanism, phenotype and therapeutic target in one coherent model and include a labelled flow diagram where appropriate.
Q7 • Metabolic Medicine • Adrenal physiology • 10 marks
Explain the mechanistic basis and its clinical consequences of HPA-axis and cortisol physiology in the context of Adrenal physiology. Illustrate how the underlying mechanism explains the clinical and laboratory phenotype.
Hpa-Axis And Cortisol Physiology — MD Final answer
1. Core concept and mechanistic basis CRH stimulates ACTH, which drives adrenal cortisol synthesis; cortisol exerts negative feedback and follows a circadian rhythm. Severe illness alters binding proteins and pulsatility. Primary adrenal failure gives low cortisol with high ACTH and often mineralocorticoid deficiency; exogenous glucocorticoids can suppress the axis and require careful tapering after prolonged exposure.
2. Pathophysiological sequence Present the sequence as trigger → molecular/cellular response → organ dysfunction → compensatory response → decompensation. Explicitly identify the rate-limiting or clinically decisive step and explain how it produces the phenotype rather than merely listing associations.
3. Clinicopathological correlation Relate the mechanism to the characteristic bedside findings and to the expected biochemical, haematological, ECG, imaging or physiological abnormalities. State which findings support the mechanism and which would suggest an alternative diagnosis.
4. Diagnostic interpretation Use pre-test probability and targeted testing. Interpret results in relation to timing, biological variation, organ function, drugs and important confounders; avoid treating a single abnormal laboratory value as diagnostic in isolation.
5. Translational and therapeutic relevance Show how understanding the pathway changes prevention, drug selection, monitoring or development of targeted therapy. Mention major safety constraints and why treatment may fail despite apparently correct pathway targeting.
6. High-yield conclusion A distinction-level answer should finish by linking mechanism, phenotype and therapeutic target in one coherent model and include a labelled flow diagram where appropriate.
Q8 • Cardiology • Coronary atherosclerosis • 10 marks
Discuss the diagnostic/interpretive framework and key pitfalls of plaque rupture, thrombosis and myocardial necrosis in the context of Coronary atherosclerosis. Illustrate how the underlying mechanism explains the clinical and laboratory phenotype.
Plaque Rupture, Thrombosis And Myocardial Necrosis — MD Final answer
1. Core concept and mechanistic basis Atherosclerosis begins with endothelial dysfunction, apoB-containing lipoprotein retention and inflammation. Thin-cap fibroatheroma with a lipid-rich necrotic core is vulnerable to rupture; tissue factor exposure triggers platelet activation and thrombin generation. Acute myocardial injury is assessed with symptoms, serial ECGs and a rise/fall in high-sensitivity troponin, while distinguishing type 1 MI from supply–demand injury and non-ischaemic myocardial injury.
2. Pathophysiological sequence Present the sequence as trigger → molecular/cellular response → organ dysfunction → compensatory response → decompensation. Explicitly identify the rate-limiting or clinically decisive step and explain how it produces the phenotype rather than merely listing associations.
3. Clinicopathological correlation Relate the mechanism to the characteristic bedside findings and to the expected biochemical, haematological, ECG, imaging or physiological abnormalities. State which findings support the mechanism and which would suggest an alternative diagnosis.
4. Diagnostic interpretation Use pre-test probability and targeted testing. Interpret results in relation to timing, biological variation, organ function, drugs and important confounders; avoid treating a single abnormal laboratory value as diagnostic in isolation.
5. Translational and therapeutic relevance Show how understanding the pathway changes prevention, drug selection, monitoring or development of targeted therapy. Mention major safety constraints and why treatment may fail despite apparently correct pathway targeting.
6. High-yield conclusion A distinction-level answer should finish by linking mechanism, phenotype and therapeutic target in one coherent model and include a labelled flow diagram where appropriate.
Q9 • Endocrinology • Glucose homeostasis • 10 marks
Integrate the topic with complications, monitoring and translational relevance of hyperosmolarity and HHS physiology in the context of Glucose homeostasis. Illustrate how the underlying mechanism explains the clinical and laboratory phenotype.
Hyperosmolarity And Hhs Physiology — MD Final answer
1. Core concept and mechanistic basis HHS results from severe insulin deficiency sufficient to permit marked hyperglycaemia but often enough to limit major ketogenesis. Osmotic diuresis causes profound water and electrolyte loss, hypertonicity and neurological dysfunction. Effective osmolality and corrected sodium guide fluid therapy; potassium must be monitored closely when insulin is started.
2. Pathophysiological sequence Present the sequence as trigger → molecular/cellular response → organ dysfunction → compensatory response → decompensation. Explicitly identify the rate-limiting or clinically decisive step and explain how it produces the phenotype rather than merely listing associations.
3. Clinicopathological correlation Relate the mechanism to the characteristic bedside findings and to the expected biochemical, haematological, ECG, imaging or physiological abnormalities. State which findings support the mechanism and which would suggest an alternative diagnosis.
4. Diagnostic interpretation Use pre-test probability and targeted testing. Interpret results in relation to timing, biological variation, organ function, drugs and important confounders; avoid treating a single abnormal laboratory value as diagnostic in isolation.
5. Translational and therapeutic relevance Show how understanding the pathway changes prevention, drug selection, monitoring or development of targeted therapy. Mention major safety constraints and why treatment may fail despite apparently correct pathway targeting.
6. High-yield conclusion A distinction-level answer should finish by linking mechanism, phenotype and therapeutic target in one coherent model and include a labelled flow diagram where appropriate.
Q10 • Pulmonology • Respiratory physiology • 10 marks
Critically appraise current management implications of hypercapnia and alveolar ventilation in the context of Respiratory physiology. Illustrate how the underlying mechanism explains the clinical and laboratory phenotype.
Hypercapnia And Alveolar Ventilation — MD Final answer
1. Core concept and mechanistic basis PaCO2 varies inversely with alveolar ventilation: PaCO2 ≈ VCO2/VA. Hypercapnia therefore reflects inadequate effective alveolar ventilation from reduced minute ventilation, increased dead space or excess CO2 production. Acute respiratory acidosis raises bicarbonate only slightly, whereas chronic renal compensation raises bicarbonate more substantially; oxygenation and ventilation must be assessed separately.
2. Pathophysiological sequence Present the sequence as trigger → molecular/cellular response → organ dysfunction → compensatory response → decompensation. Explicitly identify the rate-limiting or clinically decisive step and explain how it produces the phenotype rather than merely listing associations.
3. Clinicopathological correlation Relate the mechanism to the characteristic bedside findings and to the expected biochemical, haematological, ECG, imaging or physiological abnormalities. State which findings support the mechanism and which would suggest an alternative diagnosis.
4. Diagnostic interpretation Use pre-test probability and targeted testing. Interpret results in relation to timing, biological variation, organ function, drugs and important confounders; avoid treating a single abnormal laboratory value as diagnostic in isolation.
5. Translational and therapeutic relevance Show how understanding the pathway changes prevention, drug selection, monitoring or development of targeted therapy. Mention major safety constraints and why treatment may fail despite apparently correct pathway targeting.
6. High-yield conclusion A distinction-level answer should finish by linking mechanism, phenotype and therapeutic target in one coherent model and include a labelled flow diagram where appropriate.
SET 1 • PAPER 2
Paper 2: Comprehensive Clinical Medicine & Allied Specialties
10 Questions × 10 marks = 100 marks • 10 different specialties/domains • Strict paper-specific scope • MD Final level
Q1 • Critical Care Medicine • Critical care • 10 marks
A patient presents with a problem centered on undifferentiated shock with POCUS. Discuss the prioritized diagnostic strategy, severity assessment, evidence-based management, complications and criteria for escalation of care.
A Patient Presents With A Problem Centered On Undifferentiated Shock With Pocus — MD Final clinical answer
Clinical framing A patient presents with a problem centered on undifferentiated shock with POCUS should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Immediate priorities Assess haemodynamic and respiratory stability first; identify time-critical complications and reversible precipitants. Stabilisation should proceed in parallel with focused diagnosis when delay could cause harm.
Diagnostic strategy Define the syndrome from focused history and examination, then order investigations that establish diagnosis, severity and aetiology. Use disease-specific scores/criteria only when validated for the clinical setting, and actively exclude dangerous mimics.
Definitive management Separate supportive care, disease-modifying therapy and treatment of the precipitating cause. State indications for escalation to procedure/intervention, intensive monitoring or specialist care, and modify therapy for renal/hepatic dysfunction, pregnancy, frailty and bleeding risk where relevant.
Monitoring and complications Follow clinical response plus disease-relevant laboratory/imaging trends; monitor treatment toxicity and define objective failure/escalation criteria. Anticipate early complications as well as recurrence and long-term organ damage.
Secondary prevention and follow-up Address risk-factor modification, vaccination/prophylaxis where relevant, adherence, rehabilitation and evidence-based long-term therapy. Reassess diagnosis when the expected trajectory is not achieved.
Q2 • Neurology • Neuromuscular emergencies • 10 marks
A patient presents with a problem centered on Guillain-Barré syndrome. Discuss the prioritized diagnostic strategy, severity assessment, evidence-based management, complications and criteria for escalation of care.
A Patient Presents With A Problem Centered On Guillain-Barré Syndrome — MD Final clinical answer
Clinical framing A patient presents with a problem centered on Guillain-Barré syndrome should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Immediate priorities Assess haemodynamic and respiratory stability first; identify time-critical complications and reversible precipitants. Stabilisation should proceed in parallel with focused diagnosis when delay could cause harm.
Diagnostic strategy Define the syndrome from focused history and examination, then order investigations that establish diagnosis, severity and aetiology. Use disease-specific scores/criteria only when validated for the clinical setting, and actively exclude dangerous mimics.
Definitive management Separate supportive care, disease-modifying therapy and treatment of the precipitating cause. State indications for escalation to procedure/intervention, intensive monitoring or specialist care, and modify therapy for renal/hepatic dysfunction, pregnancy, frailty and bleeding risk where relevant.
Monitoring and complications Follow clinical response plus disease-relevant laboratory/imaging trends; monitor treatment toxicity and define objective failure/escalation criteria. Anticipate early complications as well as recurrence and long-term organ damage.
Secondary prevention and follow-up Address risk-factor modification, vaccination/prophylaxis where relevant, adherence, rehabilitation and evidence-based long-term therapy. Reassess diagnosis when the expected trajectory is not achieved.
Q3 • Adrenal & Metabolic Medicine • Adrenal disease • 10 marks
A patient presents with a problem centered on pheochromocytoma. Discuss the prioritized diagnostic strategy, severity assessment, evidence-based management, complications and criteria for escalation of care.
A Patient Presents With A Problem Centered On Pheochromocytoma — MD Final clinical answer
Clinical framing A patient presents with a problem centered on pheochromocytoma should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Immediate priorities Assess haemodynamic and respiratory stability first; identify time-critical complications and reversible precipitants. Stabilisation should proceed in parallel with focused diagnosis when delay could cause harm.
Diagnostic strategy Define the syndrome from focused history and examination, then order investigations that establish diagnosis, severity and aetiology. Use disease-specific scores/criteria only when validated for the clinical setting, and actively exclude dangerous mimics.
Definitive management Separate supportive care, disease-modifying therapy and treatment of the precipitating cause. State indications for escalation to procedure/intervention, intensive monitoring or specialist care, and modify therapy for renal/hepatic dysfunction, pregnancy, frailty and bleeding risk where relevant.
Monitoring and complications Follow clinical response plus disease-relevant laboratory/imaging trends; monitor treatment toxicity and define objective failure/escalation criteria. Anticipate early complications as well as recurrence and long-term organ damage.
Secondary prevention and follow-up Address risk-factor modification, vaccination/prophylaxis where relevant, adherence, rehabilitation and evidence-based long-term therapy. Reassess diagnosis when the expected trajectory is not achieved.
Q4 • Hepatology & Gastroenterology • Cirrhosis • 10 marks
A patient presents with a problem centered on hepatorenal syndrome-AKI. Discuss the prioritized diagnostic strategy, severity assessment, evidence-based management, complications and criteria for escalation of care.
A Patient Presents With A Problem Centered On Hepatorenal Syndrome-Aki — MD Final clinical answer
Clinical framing A patient presents with a problem centered on hepatorenal syndrome-AKI should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Immediate priorities Assess haemodynamic and respiratory stability first; identify time-critical complications and reversible precipitants. Stabilisation should proceed in parallel with focused diagnosis when delay could cause harm.
Diagnostic strategy Define the syndrome from focused history and examination, then order investigations that establish diagnosis, severity and aetiology. Use disease-specific scores/criteria only when validated for the clinical setting, and actively exclude dangerous mimics.
Definitive management Separate supportive care, disease-modifying therapy and treatment of the precipitating cause. State indications for escalation to procedure/intervention, intensive monitoring or specialist care, and modify therapy for renal/hepatic dysfunction, pregnancy, frailty and bleeding risk where relevant.
Monitoring and complications Follow clinical response plus disease-relevant laboratory/imaging trends; monitor treatment toxicity and define objective failure/escalation criteria. Anticipate early complications as well as recurrence and long-term organ damage.
Secondary prevention and follow-up Address risk-factor modification, vaccination/prophylaxis where relevant, adherence, rehabilitation and evidence-based long-term therapy. Reassess diagnosis when the expected trajectory is not achieved.
Q5 • Clinical Electrophysiology • Arrhythmias • 10 marks
A patient presents with a problem centered on atrial fibrillation with rapid ventricular response. Discuss the prioritized diagnostic strategy, severity assessment, evidence-based management, complications and criteria for escalation of care.
A Patient Presents With A Problem Centered On Atrial Fibrillation With Rapid Ventricular R — MD Final clinical answer
Clinical framing A patient presents with a problem centered on atrial fibrillation with rapid ventricular r should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Immediate priorities Assess haemodynamic and respiratory stability first; identify time-critical complications and reversible precipitants. Stabilisation should proceed in parallel with focused diagnosis when delay could cause harm.
Diagnostic strategy Define the syndrome from focused history and examination, then order investigations that establish diagnosis, severity and aetiology. Use disease-specific scores/criteria only when validated for the clinical setting, and actively exclude dangerous mimics.
Definitive management Separate supportive care, disease-modifying therapy and treatment of the precipitating cause. State indications for escalation to procedure/intervention, intensive monitoring or specialist care, and modify therapy for renal/hepatic dysfunction, pregnancy, frailty and bleeding risk where relevant.
Monitoring and complications Follow clinical response plus disease-relevant laboratory/imaging trends; monitor treatment toxicity and define objective failure/escalation criteria. Anticipate early complications as well as recurrence and long-term organ damage.
Secondary prevention and follow-up Address risk-factor modification, vaccination/prophylaxis where relevant, adherence, rehabilitation and evidence-based long-term therapy. Reassess diagnosis when the expected trajectory is not achieved.
Q6 • Nephrology • Acute kidney injury • 10 marks
A patient presents with a problem centered on septic AKI. Discuss the prioritized diagnostic strategy, severity assessment, evidence-based management, complications and criteria for escalation of care.
A Patient Presents With A Problem Centered On Septic Aki — MD Final clinical answer
Clinical framing A patient presents with a problem centered on septic AKI should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Immediate priorities Assess haemodynamic and respiratory stability first; identify time-critical complications and reversible precipitants. Stabilisation should proceed in parallel with focused diagnosis when delay could cause harm.
Diagnostic strategy Define the syndrome from focused history and examination, then order investigations that establish diagnosis, severity and aetiology. Use disease-specific scores/criteria only when validated for the clinical setting, and actively exclude dangerous mimics.
Definitive management Separate supportive care, disease-modifying therapy and treatment of the precipitating cause. State indications for escalation to procedure/intervention, intensive monitoring or specialist care, and modify therapy for renal/hepatic dysfunction, pregnancy, frailty and bleeding risk where relevant.
Monitoring and complications Follow clinical response plus disease-relevant laboratory/imaging trends; monitor treatment toxicity and define objective failure/escalation criteria. Anticipate early complications as well as recurrence and long-term organ damage.
Secondary prevention and follow-up Address risk-factor modification, vaccination/prophylaxis where relevant, adherence, rehabilitation and evidence-based long-term therapy. Reassess diagnosis when the expected trajectory is not achieved.
Q7 • Geriatric & Perioperative Medicine • Geriatric and perioperative medicine • 10 marks
A patient presents with a problem centered on delirium. Discuss the prioritized diagnostic strategy, severity assessment, evidence-based management, complications and criteria for escalation of care.
A Patient Presents With A Problem Centered On Delirium — MD Final clinical answer
Clinical framing A patient presents with a problem centered on delirium should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Immediate priorities Assess haemodynamic and respiratory stability first; identify time-critical complications and reversible precipitants. Stabilisation should proceed in parallel with focused diagnosis when delay could cause harm.
Diagnostic strategy Define the syndrome from focused history and examination, then order investigations that establish diagnosis, severity and aetiology. Use disease-specific scores/criteria only when validated for the clinical setting, and actively exclude dangerous mimics.
Definitive management Separate supportive care, disease-modifying therapy and treatment of the precipitating cause. State indications for escalation to procedure/intervention, intensive monitoring or specialist care, and modify therapy for renal/hepatic dysfunction, pregnancy, frailty and bleeding risk where relevant.
Monitoring and complications Follow clinical response plus disease-relevant laboratory/imaging trends; monitor treatment toxicity and define objective failure/escalation criteria. Anticipate early complications as well as recurrence and long-term organ damage.
Secondary prevention and follow-up Address risk-factor modification, vaccination/prophylaxis where relevant, adherence, rehabilitation and evidence-based long-term therapy. Reassess diagnosis when the expected trajectory is not achieved.
Q8 • Rheumatology • Rheumatology • 10 marks
A patient presents with a problem centered on systemic sclerosis with renal crisis. Discuss the prioritized diagnostic strategy, severity assessment, evidence-based management, complications and criteria for escalation of care.
A Patient Presents With A Problem Centered On Systemic Sclerosis With Renal Crisis — MD Final clinical answer
Clinical framing A patient presents with a problem centered on systemic sclerosis with renal crisis should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Immediate priorities Assess haemodynamic and respiratory stability first; identify time-critical complications and reversible precipitants. Stabilisation should proceed in parallel with focused diagnosis when delay could cause harm.
Diagnostic strategy Define the syndrome from focused history and examination, then order investigations that establish diagnosis, severity and aetiology. Use disease-specific scores/criteria only when validated for the clinical setting, and actively exclude dangerous mimics.
Definitive management Separate supportive care, disease-modifying therapy and treatment of the precipitating cause. State indications for escalation to procedure/intervention, intensive monitoring or specialist care, and modify therapy for renal/hepatic dysfunction, pregnancy, frailty and bleeding risk where relevant.
Monitoring and complications Follow clinical response plus disease-relevant laboratory/imaging trends; monitor treatment toxicity and define objective failure/escalation criteria. Anticipate early complications as well as recurrence and long-term organ damage.
Secondary prevention and follow-up Address risk-factor modification, vaccination/prophylaxis where relevant, adherence, rehabilitation and evidence-based long-term therapy. Reassess diagnosis when the expected trajectory is not achieved.
Q9 • Vascular & Hypertension Medicine • Hypertension • 10 marks
A patient presents with a problem centered on hypertension in CKD. Discuss the prioritized diagnostic strategy, severity assessment, evidence-based management, complications and criteria for escalation of care.
A Patient Presents With A Problem Centered On Hypertension In Ckd — MD Final clinical answer
Clinical framing A patient presents with a problem centered on hypertension in CKD should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Immediate priorities Assess haemodynamic and respiratory stability first; identify time-critical complications and reversible precipitants. Stabilisation should proceed in parallel with focused diagnosis when delay could cause harm.
Diagnostic strategy Define the syndrome from focused history and examination, then order investigations that establish diagnosis, severity and aetiology. Use disease-specific scores/criteria only when validated for the clinical setting, and actively exclude dangerous mimics.
Definitive management Separate supportive care, disease-modifying therapy and treatment of the precipitating cause. State indications for escalation to procedure/intervention, intensive monitoring or specialist care, and modify therapy for renal/hepatic dysfunction, pregnancy, frailty and bleeding risk where relevant.
Monitoring and complications Follow clinical response plus disease-relevant laboratory/imaging trends; monitor treatment toxicity and define objective failure/escalation criteria. Anticipate early complications as well as recurrence and long-term organ damage.
Secondary prevention and follow-up Address risk-factor modification, vaccination/prophylaxis where relevant, adherence, rehabilitation and evidence-based long-term therapy. Reassess diagnosis when the expected trajectory is not achieved.
Q10 • Pulmonology • COPD • 10 marks
A patient presents with a problem centered on stable COPD multidimensional assessment. Discuss the prioritized diagnostic strategy, severity assessment, evidence-based management, complications and criteria for escalation of care.
A Patient Presents With A Problem Centered On Stable Copd Multidimensional Assessment — MD Final clinical answer
Clinical framing A patient presents with a problem centered on stable COPD multidimensional assessment should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Immediate priorities Assess haemodynamic and respiratory stability first; identify time-critical complications and reversible precipitants. Stabilisation should proceed in parallel with focused diagnosis when delay could cause harm.
Diagnostic strategy Define the syndrome from focused history and examination, then order investigations that establish diagnosis, severity and aetiology. Use disease-specific scores/criteria only when validated for the clinical setting, and actively exclude dangerous mimics.
Definitive management Separate supportive care, disease-modifying therapy and treatment of the precipitating cause. State indications for escalation to procedure/intervention, intensive monitoring or specialist care, and modify therapy for renal/hepatic dysfunction, pregnancy, frailty and bleeding risk where relevant.
Monitoring and complications Follow clinical response plus disease-relevant laboratory/imaging trends; monitor treatment toxicity and define objective failure/escalation criteria. Anticipate early complications as well as recurrence and long-term organ damage.
Secondary prevention and follow-up Address risk-factor modification, vaccination/prophylaxis where relevant, adherence, rehabilitation and evidence-based long-term therapy. Reassess diagnosis when the expected trajectory is not achieved.
SET 1 • PAPER 3
Paper 3: Infectious & Tropical Medicine
10 Questions × 10 marks = 100 marks • 10 different specialties/domains • Strict paper-specific scope • MD Final level
Discuss cholera with severe dehydration under epidemiology/risk, clinical syndrome, definitive diagnosis, pathogen-directed treatment, complications, prevention and antimicrobial-stewardship considerations.
Discuss Cholera With Severe Dehydration Under Epidemiology/Risk, Clinical Syndrome, Defini — MD Final infectious/tropical medicine answer
Pathogen–host framework Discuss cholera with severe dehydration under epidemiology/risk, clinical syndrome, defini should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Clinical syndrome and severity Define exposure/epidemiology, incubation where relevant, immune status and organ involvement. Identify shock, encephalopathy, respiratory failure, bleeding, AKI, severe jaundice or other organ dysfunction requiring urgent escalation.
Microbiological diagnosis Obtain the highest-yield specimen before antimicrobials when this does not delay lifesaving treatment. Choose microscopy/culture, antigen, serology or nucleic-acid testing according to disease phase; interpret colonisation, contamination, cross-reactivity and prior antimicrobial exposure.
Specific therapy Start empiric treatment when severity and pre-test probability justify it, then narrow or stop therapy using microbiology and clinical response. Account for local resistance, source control, CNS penetration, renal/hepatic adjustment, drug interactions and toxicity. Avoid unnecessary combination or prolonged therapy.
Complications and public-health measures Monitor organ dysfunction and treatment-related complications. Include isolation, notification, vector control, contact management, vaccination or chemoprophylaxis when applicable.
Exam conclusion A high-scoring answer integrates epidemiology, stage-appropriate diagnostics, severity-based treatment and antimicrobial stewardship rather than presenting an undifferentiated drug list.
Discuss Weil disease under epidemiology/risk, clinical syndrome, definitive diagnosis, pathogen-directed treatment, complications, prevention and antimicrobial-stewardship considerations.
Discuss Weil Disease Under Epidemiology/Risk, Clinical Syndrome, Definitive Diagnosis, Pat — MD Final infectious/tropical medicine answer
Pathogen–host framework Discuss Weil disease under epidemiology/risk, clinical syndrome, definitive diagnosis, pat should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Clinical syndrome and severity Define exposure/epidemiology, incubation where relevant, immune status and organ involvement. Identify shock, encephalopathy, respiratory failure, bleeding, AKI, severe jaundice or other organ dysfunction requiring urgent escalation.
Microbiological diagnosis Obtain the highest-yield specimen before antimicrobials when this does not delay lifesaving treatment. Choose microscopy/culture, antigen, serology or nucleic-acid testing according to disease phase; interpret colonisation, contamination, cross-reactivity and prior antimicrobial exposure.
Specific therapy Start empiric treatment when severity and pre-test probability justify it, then narrow or stop therapy using microbiology and clinical response. Account for local resistance, source control, CNS penetration, renal/hepatic adjustment, drug interactions and toxicity. Avoid unnecessary combination or prolonged therapy.
Complications and public-health measures Monitor organ dysfunction and treatment-related complications. Include isolation, notification, vector control, contact management, vaccination or chemoprophylaxis when applicable.
Exam conclusion A high-scoring answer integrates epidemiology, stage-appropriate diagnostics, severity-based treatment and antimicrobial stewardship rather than presenting an undifferentiated drug list.
Q3 • Arboviral & Tropical Fever Medicine • Dengue • 10 marks
Discuss dengue shock syndrome under epidemiology/risk, clinical syndrome, definitive diagnosis, pathogen-directed treatment, complications, prevention and antimicrobial-stewardship considerations.
Discuss Dengue Shock Syndrome Under Epidemiology/Risk, Clinical Syndrome, Definitive Diagn — MD Final infectious/tropical medicine answer
Pathogen–host framework Discuss dengue shock syndrome under epidemiology/risk, clinical syndrome, definitive diagn should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Clinical syndrome and severity Define exposure/epidemiology, incubation where relevant, immune status and organ involvement. Identify shock, encephalopathy, respiratory failure, bleeding, AKI, severe jaundice or other organ dysfunction requiring urgent escalation.
Microbiological diagnosis Obtain the highest-yield specimen before antimicrobials when this does not delay lifesaving treatment. Choose microscopy/culture, antigen, serology or nucleic-acid testing according to disease phase; interpret colonisation, contamination, cross-reactivity and prior antimicrobial exposure.
Specific therapy Start empiric treatment when severity and pre-test probability justify it, then narrow or stop therapy using microbiology and clinical response. Account for local resistance, source control, CNS penetration, renal/hepatic adjustment, drug interactions and toxicity. Avoid unnecessary combination or prolonged therapy.
Complications and public-health measures Monitor organ dysfunction and treatment-related complications. Include isolation, notification, vector control, contact management, vaccination or chemoprophylaxis when applicable.
Exam conclusion A high-scoring answer integrates epidemiology, stage-appropriate diagnostics, severity-based treatment and antimicrobial stewardship rather than presenting an undifferentiated drug list.
Discuss catheter-associated UTI under epidemiology/risk, clinical syndrome, definitive diagnosis, pathogen-directed treatment, complications, prevention and antimicrobial-stewardship considerations.
Discuss Catheter-Associated Uti Under Epidemiology/Risk, Clinical Syndrome, Definitive Dia — MD Final infectious/tropical medicine answer
Pathogen–host framework Discuss catheter-associated UTI under epidemiology/risk, clinical syndrome, definitive dia should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Clinical syndrome and severity Define exposure/epidemiology, incubation where relevant, immune status and organ involvement. Identify shock, encephalopathy, respiratory failure, bleeding, AKI, severe jaundice or other organ dysfunction requiring urgent escalation.
Microbiological diagnosis Obtain the highest-yield specimen before antimicrobials when this does not delay lifesaving treatment. Choose microscopy/culture, antigen, serology or nucleic-acid testing according to disease phase; interpret colonisation, contamination, cross-reactivity and prior antimicrobial exposure.
Specific therapy Start empiric treatment when severity and pre-test probability justify it, then narrow or stop therapy using microbiology and clinical response. Account for local resistance, source control, CNS penetration, renal/hepatic adjustment, drug interactions and toxicity. Avoid unnecessary combination or prolonged therapy.
Complications and public-health measures Monitor organ dysfunction and treatment-related complications. Include isolation, notification, vector control, contact management, vaccination or chemoprophylaxis when applicable.
Exam conclusion A high-scoring answer integrates epidemiology, stage-appropriate diagnostics, severity-based treatment and antimicrobial stewardship rather than presenting an undifferentiated drug list.
Q5 • Respiratory Infectious Disease • Pneumonia • 10 marks
Discuss aspiration pneumonia under epidemiology/risk, clinical syndrome, definitive diagnosis, pathogen-directed treatment, complications, prevention and antimicrobial-stewardship considerations.
Discuss Aspiration Pneumonia Under Epidemiology/Risk, Clinical Syndrome, Definitive Diagno — MD Final infectious/tropical medicine answer
Pathogen–host framework Discuss aspiration pneumonia under epidemiology/risk, clinical syndrome, definitive diagno should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Clinical syndrome and severity Define exposure/epidemiology, incubation where relevant, immune status and organ involvement. Identify shock, encephalopathy, respiratory failure, bleeding, AKI, severe jaundice or other organ dysfunction requiring urgent escalation.
Microbiological diagnosis Obtain the highest-yield specimen before antimicrobials when this does not delay lifesaving treatment. Choose microscopy/culture, antigen, serology or nucleic-acid testing according to disease phase; interpret colonisation, contamination, cross-reactivity and prior antimicrobial exposure.
Specific therapy Start empiric treatment when severity and pre-test probability justify it, then narrow or stop therapy using microbiology and clinical response. Account for local resistance, source control, CNS penetration, renal/hepatic adjustment, drug interactions and toxicity. Avoid unnecessary combination or prolonged therapy.
Complications and public-health measures Monitor organ dysfunction and treatment-related complications. Include isolation, notification, vector control, contact management, vaccination or chemoprophylaxis when applicable.
Exam conclusion A high-scoring answer integrates epidemiology, stage-appropriate diagnostics, severity-based treatment and antimicrobial stewardship rather than presenting an undifferentiated drug list.
Q6 • Parasitic Gastroenterology • Amoebiasis • 10 marks
Discuss ruptured liver abscess under epidemiology/risk, clinical syndrome, definitive diagnosis, pathogen-directed treatment, complications, prevention and antimicrobial-stewardship considerations.
Discuss Ruptured Liver Abscess Under Epidemiology/Risk, Clinical Syndrome, Definitive Diag — MD Final infectious/tropical medicine answer
Pathogen–host framework Discuss ruptured liver abscess under epidemiology/risk, clinical syndrome, definitive diag should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Clinical syndrome and severity Define exposure/epidemiology, incubation where relevant, immune status and organ involvement. Identify shock, encephalopathy, respiratory failure, bleeding, AKI, severe jaundice or other organ dysfunction requiring urgent escalation.
Microbiological diagnosis Obtain the highest-yield specimen before antimicrobials when this does not delay lifesaving treatment. Choose microscopy/culture, antigen, serology or nucleic-acid testing according to disease phase; interpret colonisation, contamination, cross-reactivity and prior antimicrobial exposure.
Specific therapy Start empiric treatment when severity and pre-test probability justify it, then narrow or stop therapy using microbiology and clinical response. Account for local resistance, source control, CNS penetration, renal/hepatic adjustment, drug interactions and toxicity. Avoid unnecessary combination or prolonged therapy.
Complications and public-health measures Monitor organ dysfunction and treatment-related complications. Include isolation, notification, vector control, contact management, vaccination or chemoprophylaxis when applicable.
Exam conclusion A high-scoring answer integrates epidemiology, stage-appropriate diagnostics, severity-based treatment and antimicrobial stewardship rather than presenting an undifferentiated drug list.
Discuss Nipah virus preparedness under epidemiology/risk, clinical syndrome, definitive diagnosis, pathogen-directed treatment, complications, prevention and antimicrobial-stewardship considerations.
Discuss Nipah Virus Preparedness Under Epidemiology/Risk, Clinical Syndrome, Definitive Di — MD Final infectious/tropical medicine answer
Pathogen–host framework Discuss Nipah virus preparedness under epidemiology/risk, clinical syndrome, definitive di should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Clinical syndrome and severity Define exposure/epidemiology, incubation where relevant, immune status and organ involvement. Identify shock, encephalopathy, respiratory failure, bleeding, AKI, severe jaundice or other organ dysfunction requiring urgent escalation.
Microbiological diagnosis Obtain the highest-yield specimen before antimicrobials when this does not delay lifesaving treatment. Choose microscopy/culture, antigen, serology or nucleic-acid testing according to disease phase; interpret colonisation, contamination, cross-reactivity and prior antimicrobial exposure.
Specific therapy Start empiric treatment when severity and pre-test probability justify it, then narrow or stop therapy using microbiology and clinical response. Account for local resistance, source control, CNS penetration, renal/hepatic adjustment, drug interactions and toxicity. Avoid unnecessary combination or prolonged therapy.
Complications and public-health measures Monitor organ dysfunction and treatment-related complications. Include isolation, notification, vector control, contact management, vaccination or chemoprophylaxis when applicable.
Exam conclusion A high-scoring answer integrates epidemiology, stage-appropriate diagnostics, severity-based treatment and antimicrobial stewardship rather than presenting an undifferentiated drug list.
Q8 • Critical Care Infectious Disease • Sepsis • 10 marks
Discuss antimicrobial de-escalation under epidemiology/risk, clinical syndrome, definitive diagnosis, pathogen-directed treatment, complications, prevention and antimicrobial-stewardship considerations.
Discuss Antimicrobial De-Escalation Under Epidemiology/Risk, Clinical Syndrome, Definitive — MD Final infectious/tropical medicine answer
Pathogen–host framework Discuss antimicrobial de-escalation under epidemiology/risk, clinical syndrome, definitive should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Clinical syndrome and severity Define exposure/epidemiology, incubation where relevant, immune status and organ involvement. Identify shock, encephalopathy, respiratory failure, bleeding, AKI, severe jaundice or other organ dysfunction requiring urgent escalation.
Microbiological diagnosis Obtain the highest-yield specimen before antimicrobials when this does not delay lifesaving treatment. Choose microscopy/culture, antigen, serology or nucleic-acid testing according to disease phase; interpret colonisation, contamination, cross-reactivity and prior antimicrobial exposure.
Specific therapy Start empiric treatment when severity and pre-test probability justify it, then narrow or stop therapy using microbiology and clinical response. Account for local resistance, source control, CNS penetration, renal/hepatic adjustment, drug interactions and toxicity. Avoid unnecessary combination or prolonged therapy.
Complications and public-health measures Monitor organ dysfunction and treatment-related complications. Include isolation, notification, vector control, contact management, vaccination or chemoprophylaxis when applicable.
Exam conclusion A high-scoring answer integrates epidemiology, stage-appropriate diagnostics, severity-based treatment and antimicrobial stewardship rather than presenting an undifferentiated drug list.
Q9 • Hematologic Tropical Medicine • Kala-azar • 10 marks
Discuss visceral leishmaniasis with HIV under epidemiology/risk, clinical syndrome, definitive diagnosis, pathogen-directed treatment, complications, prevention and antimicrobial-stewardship considerations.
Discuss Visceral Leishmaniasis With Hiv Under Epidemiology/Risk, Clinical Syndrome, Defini — MD Final infectious/tropical medicine answer
Pathogen–host framework Discuss visceral leishmaniasis with HIV under epidemiology/risk, clinical syndrome, defini should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Clinical syndrome and severity Define exposure/epidemiology, incubation where relevant, immune status and organ involvement. Identify shock, encephalopathy, respiratory failure, bleeding, AKI, severe jaundice or other organ dysfunction requiring urgent escalation.
Microbiological diagnosis Obtain the highest-yield specimen before antimicrobials when this does not delay lifesaving treatment. Choose microscopy/culture, antigen, serology or nucleic-acid testing according to disease phase; interpret colonisation, contamination, cross-reactivity and prior antimicrobial exposure.
Specific therapy Start empiric treatment when severity and pre-test probability justify it, then narrow or stop therapy using microbiology and clinical response. Account for local resistance, source control, CNS penetration, renal/hepatic adjustment, drug interactions and toxicity. Avoid unnecessary combination or prolonged therapy.
Complications and public-health measures Monitor organ dysfunction and treatment-related complications. Include isolation, notification, vector control, contact management, vaccination or chemoprophylaxis when applicable.
Exam conclusion A high-scoring answer integrates epidemiology, stage-appropriate diagnostics, severity-based treatment and antimicrobial stewardship rather than presenting an undifferentiated drug list.
Q10 • Neuroinfectious Disease • Japanese encephalitis • 10 marks
Discuss JE neurocritical care under epidemiology/risk, clinical syndrome, definitive diagnosis, pathogen-directed treatment, complications, prevention and antimicrobial-stewardship considerations.
Discuss Je Neurocritical Care Under Epidemiology/Risk, Clinical Syndrome, Definitive Diagn — MD Final infectious/tropical medicine answer
Pathogen–host framework Discuss JE neurocritical care under epidemiology/risk, clinical syndrome, definitive diagn should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Clinical syndrome and severity Define exposure/epidemiology, incubation where relevant, immune status and organ involvement. Identify shock, encephalopathy, respiratory failure, bleeding, AKI, severe jaundice or other organ dysfunction requiring urgent escalation.
Microbiological diagnosis Obtain the highest-yield specimen before antimicrobials when this does not delay lifesaving treatment. Choose microscopy/culture, antigen, serology or nucleic-acid testing according to disease phase; interpret colonisation, contamination, cross-reactivity and prior antimicrobial exposure.
Specific therapy Start empiric treatment when severity and pre-test probability justify it, then narrow or stop therapy using microbiology and clinical response. Account for local resistance, source control, CNS penetration, renal/hepatic adjustment, drug interactions and toxicity. Avoid unnecessary combination or prolonged therapy.
Complications and public-health measures Monitor organ dysfunction and treatment-related complications. Include isolation, notification, vector control, contact management, vaccination or chemoprophylaxis when applicable.
Exam conclusion A high-scoring answer integrates epidemiology, stage-appropriate diagnostics, severity-based treatment and antimicrobial stewardship rather than presenting an undifferentiated drug list.
SET 1 • PAPER 4
Paper 4: Recent Advances, Contemporary Therapeutics, Diagnostics & Precision Medicine
10 Questions × 10 marks = 100 marks • 10 different specialties/domains • Strict paper-specific scope • MD Final level
Q1 • Metabolic & Obesity Medicine • Obesity medicine • 10 marks
Critically appraise cardiovascular outcome evidence in obesity: mechanism/technology, patient selection, evidence of benefit, safety/limitations, monitoring and its present place in precision Internal Medicine.
Cardiovascular Outcome Evidence In Obesity — contemporary MD appraisal
What is new and why it matters cardiovascular outcome evidence in obesity should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Mechanism / technology Define the biological target, diagnostic principle or device mechanism and the specific clinical problem it is intended to solve. Distinguish mechanistic plausibility from demonstrated patient benefit.
Evidence and patient selection Describe the population in whom benefit has been shown, the clinically important endpoint, comparator and direction of effect. Discuss external validity, important exclusions and whether evidence supports routine care, selected use or remains investigational.
Practical implementation State eligibility, contraindications, baseline assessment, monitoring and clinically important adverse effects/interactions. For diagnostics, discuss sensitivity/specificity, pre-test probability, false positives/negatives and whether the result changes management.
Precision-medicine perspective Explain how phenotype, genotype, biomarker, comorbidity or treatment-response data can refine selection. Include access, cost, equity and feasibility—especially in resource-limited practice.
Critical conclusion Place the advance against current standard care, identify one unresolved evidence gap and avoid equating novelty with superiority.
Q2 • Tuberculosis & Tropical Medicine • TB innovation • 10 marks
Critically appraise molecular resistance testing: mechanism/technology, patient selection, evidence of benefit, safety/limitations, monitoring and its present place in precision Internal Medicine.
What is new and why it matters molecular resistance testing should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Mechanism / technology Define the biological target, diagnostic principle or device mechanism and the specific clinical problem it is intended to solve. Distinguish mechanistic plausibility from demonstrated patient benefit.
Evidence and patient selection Describe the population in whom benefit has been shown, the clinically important endpoint, comparator and direction of effect. Discuss external validity, important exclusions and whether evidence supports routine care, selected use or remains investigational.
Practical implementation State eligibility, contraindications, baseline assessment, monitoring and clinically important adverse effects/interactions. For diagnostics, discuss sensitivity/specificity, pre-test probability, false positives/negatives and whether the result changes management.
Precision-medicine perspective Explain how phenotype, genotype, biomarker, comorbidity or treatment-response data can refine selection. Include access, cost, equity and feasibility—especially in resource-limited practice.
Critical conclusion Place the advance against current standard care, identify one unresolved evidence gap and avoid equating novelty with superiority.
Q3 • Cardiology • Heart failure innovation • 10 marks
Critically appraise transcatheter therapies in structural heart disease: mechanism/technology, patient selection, evidence of benefit, safety/limitations, monitoring and its present place in precision Internal Medicine.
Transcatheter Therapies In Structural Heart Disease — contemporary MD appraisal
What is new and why it matters transcatheter therapies in structural heart disease should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Mechanism / technology Define the biological target, diagnostic principle or device mechanism and the specific clinical problem it is intended to solve. Distinguish mechanistic plausibility from demonstrated patient benefit.
Evidence and patient selection Describe the population in whom benefit has been shown, the clinically important endpoint, comparator and direction of effect. Discuss external validity, important exclusions and whether evidence supports routine care, selected use or remains investigational.
Practical implementation State eligibility, contraindications, baseline assessment, monitoring and clinically important adverse effects/interactions. For diagnostics, discuss sensitivity/specificity, pre-test probability, false positives/negatives and whether the result changes management.
Precision-medicine perspective Explain how phenotype, genotype, biomarker, comorbidity or treatment-response data can refine selection. Include access, cost, equity and feasibility—especially in resource-limited practice.
Critical conclusion Place the advance against current standard care, identify one unresolved evidence gap and avoid equating novelty with superiority.
Q4 • Pulmonology & Allergy • COPD contemporary care • 10 marks
Critically appraise endobronchial lung-volume reduction: mechanism/technology, patient selection, evidence of benefit, safety/limitations, monitoring and its present place in precision Internal Medicine.
What is new and why it matters endobronchial lung-volume reduction should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Mechanism / technology Define the biological target, diagnostic principle or device mechanism and the specific clinical problem it is intended to solve. Distinguish mechanistic plausibility from demonstrated patient benefit.
Evidence and patient selection Describe the population in whom benefit has been shown, the clinically important endpoint, comparator and direction of effect. Discuss external validity, important exclusions and whether evidence supports routine care, selected use or remains investigational.
Practical implementation State eligibility, contraindications, baseline assessment, monitoring and clinically important adverse effects/interactions. For diagnostics, discuss sensitivity/specificity, pre-test probability, false positives/negatives and whether the result changes management.
Precision-medicine perspective Explain how phenotype, genotype, biomarker, comorbidity or treatment-response data can refine selection. Include access, cost, equity and feasibility—especially in resource-limited practice.
Critical conclusion Place the advance against current standard care, identify one unresolved evidence gap and avoid equating novelty with superiority.
Q5 • Neurology • Neurology innovation • 10 marks
Critically appraise anti-amyloid monoclonal antibodies: mechanism/technology, patient selection, evidence of benefit, safety/limitations, monitoring and its present place in precision Internal Medicine.
What is new and why it matters anti-amyloid monoclonal antibodies should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Mechanism / technology Define the biological target, diagnostic principle or device mechanism and the specific clinical problem it is intended to solve. Distinguish mechanistic plausibility from demonstrated patient benefit.
Evidence and patient selection Describe the population in whom benefit has been shown, the clinically important endpoint, comparator and direction of effect. Discuss external validity, important exclusions and whether evidence supports routine care, selected use or remains investigational.
Practical implementation State eligibility, contraindications, baseline assessment, monitoring and clinically important adverse effects/interactions. For diagnostics, discuss sensitivity/specificity, pre-test probability, false positives/negatives and whether the result changes management.
Precision-medicine perspective Explain how phenotype, genotype, biomarker, comorbidity or treatment-response data can refine selection. Include access, cost, equity and feasibility—especially in resource-limited practice.
Critical conclusion Place the advance against current standard care, identify one unresolved evidence gap and avoid equating novelty with superiority.
Critically appraise host-response biomarkers: mechanism/technology, patient selection, evidence of benefit, safety/limitations, monitoring and its present place in precision Internal Medicine.
What is new and why it matters host-response biomarkers should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Mechanism / technology Define the biological target, diagnostic principle or device mechanism and the specific clinical problem it is intended to solve. Distinguish mechanistic plausibility from demonstrated patient benefit.
Evidence and patient selection Describe the population in whom benefit has been shown, the clinically important endpoint, comparator and direction of effect. Discuss external validity, important exclusions and whether evidence supports routine care, selected use or remains investigational.
Practical implementation State eligibility, contraindications, baseline assessment, monitoring and clinically important adverse effects/interactions. For diagnostics, discuss sensitivity/specificity, pre-test probability, false positives/negatives and whether the result changes management.
Precision-medicine perspective Explain how phenotype, genotype, biomarker, comorbidity or treatment-response data can refine selection. Include access, cost, equity and feasibility—especially in resource-limited practice.
Critical conclusion Place the advance against current standard care, identify one unresolved evidence gap and avoid equating novelty with superiority.
Q7 • Endocrinology • Diabetes technology • 10 marks
Critically appraise continuous glucose monitoring: mechanism/technology, patient selection, evidence of benefit, safety/limitations, monitoring and its present place in precision Internal Medicine.
What is new and why it matters continuous glucose monitoring should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Mechanism / technology Define the biological target, diagnostic principle or device mechanism and the specific clinical problem it is intended to solve. Distinguish mechanistic plausibility from demonstrated patient benefit.
Evidence and patient selection Describe the population in whom benefit has been shown, the clinically important endpoint, comparator and direction of effect. Discuss external validity, important exclusions and whether evidence supports routine care, selected use or remains investigational.
Practical implementation State eligibility, contraindications, baseline assessment, monitoring and clinically important adverse effects/interactions. For diagnostics, discuss sensitivity/specificity, pre-test probability, false positives/negatives and whether the result changes management.
Precision-medicine perspective Explain how phenotype, genotype, biomarker, comorbidity or treatment-response data can refine selection. Include access, cost, equity and feasibility—especially in resource-limited practice.
Critical conclusion Place the advance against current standard care, identify one unresolved evidence gap and avoid equating novelty with superiority.
Q8 • Hypertension & Digital Cardiovascular Medicine • Hypertension technology • 10 marks
Critically appraise single-pill combination therapy: mechanism/technology, patient selection, evidence of benefit, safety/limitations, monitoring and its present place in precision Internal Medicine.
What is new and why it matters single-pill combination therapy should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Mechanism / technology Define the biological target, diagnostic principle or device mechanism and the specific clinical problem it is intended to solve. Distinguish mechanistic plausibility from demonstrated patient benefit.
Evidence and patient selection Describe the population in whom benefit has been shown, the clinically important endpoint, comparator and direction of effect. Discuss external validity, important exclusions and whether evidence supports routine care, selected use or remains investigational.
Practical implementation State eligibility, contraindications, baseline assessment, monitoring and clinically important adverse effects/interactions. For diagnostics, discuss sensitivity/specificity, pre-test probability, false positives/negatives and whether the result changes management.
Precision-medicine perspective Explain how phenotype, genotype, biomarker, comorbidity or treatment-response data can refine selection. Include access, cost, equity and feasibility—especially in resource-limited practice.
Critical conclusion Place the advance against current standard care, identify one unresolved evidence gap and avoid equating novelty with superiority.
Q9 • Medical Oncology • Oncology immunotherapy • 10 marks
Critically appraise immune checkpoint inhibitors: mechanism/technology, patient selection, evidence of benefit, safety/limitations, monitoring and its present place in precision Internal Medicine.
What is new and why it matters immune checkpoint inhibitors should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Mechanism / technology Define the biological target, diagnostic principle or device mechanism and the specific clinical problem it is intended to solve. Distinguish mechanistic plausibility from demonstrated patient benefit.
Evidence and patient selection Describe the population in whom benefit has been shown, the clinically important endpoint, comparator and direction of effect. Discuss external validity, important exclusions and whether evidence supports routine care, selected use or remains investigational.
Practical implementation State eligibility, contraindications, baseline assessment, monitoring and clinically important adverse effects/interactions. For diagnostics, discuss sensitivity/specificity, pre-test probability, false positives/negatives and whether the result changes management.
Precision-medicine perspective Explain how phenotype, genotype, biomarker, comorbidity or treatment-response data can refine selection. Include access, cost, equity and feasibility—especially in resource-limited practice.
Critical conclusion Place the advance against current standard care, identify one unresolved evidence gap and avoid equating novelty with superiority.
Q10 • Genomic Medicine • Genomic medicine • 10 marks
Critically appraise whole-exome sequencing in adult medicine: mechanism/technology, patient selection, evidence of benefit, safety/limitations, monitoring and its present place in precision Internal Medicine.
Whole-Exome Sequencing In Adult Medicine — contemporary MD appraisal
What is new and why it matters whole-exome sequencing in adult medicine should be analysed from mechanism to phenotype rather than as an isolated fact. Define the relevant normal physiology, identify the dominant cellular or organ-level disturbance, and then connect that disturbance to the expected symptoms, examination findings, laboratory pattern and imaging/physiological abnormalities.
Mechanism / technology Define the biological target, diagnostic principle or device mechanism and the specific clinical problem it is intended to solve. Distinguish mechanistic plausibility from demonstrated patient benefit.
Evidence and patient selection Describe the population in whom benefit has been shown, the clinically important endpoint, comparator and direction of effect. Discuss external validity, important exclusions and whether evidence supports routine care, selected use or remains investigational.
Practical implementation State eligibility, contraindications, baseline assessment, monitoring and clinically important adverse effects/interactions. For diagnostics, discuss sensitivity/specificity, pre-test probability, false positives/negatives and whether the result changes management.
Precision-medicine perspective Explain how phenotype, genotype, biomarker, comorbidity or treatment-response data can refine selection. Include access, cost, equity and feasibility—especially in resource-limited practice.
Critical conclusion Place the advance against current standard care, identify one unresolved evidence gap and avoid equating novelty with superiority.